nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—systemic scleroderma—ankylosing spondylitis	0.321	0.387	CtDrD
Leflunomide—systemic lupus erythematosus—ankylosing spondylitis	0.261	0.315	CtDrD
Leflunomide—rheumatoid arthritis—ankylosing spondylitis	0.247	0.298	CtDrD
Leflunomide—ABCG2—Sulfasalazine—ankylosing spondylitis	0.0463	0.479	CbGbCtD
Leflunomide—ABCG2—Dexamethasone—ankylosing spondylitis	0.0231	0.239	CbGbCtD
Leflunomide—ABCG2—Methotrexate—ankylosing spondylitis	0.0186	0.192	CbGbCtD
Leflunomide—CYP2C9—Dexamethasone—ankylosing spondylitis	0.00859	0.0889	CbGbCtD
Leflunomide—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	8.85e-05	0.00119	CcSEcCtD
Leflunomide—Dry mouth—Triamcinolone—ankylosing spondylitis	8.8e-05	0.00118	CcSEcCtD
Leflunomide—Renal failure—Methotrexate—ankylosing spondylitis	8.78e-05	0.00118	CcSEcCtD
Leflunomide—Angioedema—Betamethasone—ankylosing spondylitis	8.76e-05	0.00117	CcSEcCtD
Leflunomide—Angioedema—Dexamethasone—ankylosing spondylitis	8.76e-05	0.00117	CcSEcCtD
Leflunomide—Stomatitis—Methotrexate—ankylosing spondylitis	8.7e-05	0.00117	CcSEcCtD
Leflunomide—Conjunctivitis—Methotrexate—ankylosing spondylitis	8.68e-05	0.00116	CcSEcCtD
Leflunomide—Immune system disorder—Prednisone—ankylosing spondylitis	8.66e-05	0.00116	CcSEcCtD
Leflunomide—Malaise—Dexamethasone—ankylosing spondylitis	8.65e-05	0.00116	CcSEcCtD
Leflunomide—Malaise—Betamethasone—ankylosing spondylitis	8.65e-05	0.00116	CcSEcCtD
Leflunomide—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	8.62e-05	0.00115	CcSEcCtD
Leflunomide—Vertigo—Dexamethasone—ankylosing spondylitis	8.61e-05	0.00115	CcSEcCtD
Leflunomide—Vertigo—Betamethasone—ankylosing spondylitis	8.61e-05	0.00115	CcSEcCtD
Leflunomide—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	8.6e-05	0.00115	CcSEcCtD
Leflunomide—Arrhythmia—Prednisone—ankylosing spondylitis	8.57e-05	0.00115	CcSEcCtD
Leflunomide—Infection—Triamcinolone—ankylosing spondylitis	8.57e-05	0.00115	CcSEcCtD
Leflunomide—Infection—Methylprednisolone—ankylosing spondylitis	8.55e-05	0.00114	CcSEcCtD
Leflunomide—Haematuria—Methotrexate—ankylosing spondylitis	8.51e-05	0.00114	CcSEcCtD
Leflunomide—Insomnia—Prednisolone—ankylosing spondylitis	8.48e-05	0.00114	CcSEcCtD
Leflunomide—Alopecia—Prednisone—ankylosing spondylitis	8.48e-05	0.00113	CcSEcCtD
Leflunomide—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	8.44e-05	0.00113	CcSEcCtD
Leflunomide—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	8.44e-05	0.00113	CcSEcCtD
Leflunomide—Epistaxis—Methotrexate—ankylosing spondylitis	8.42e-05	0.00113	CcSEcCtD
Leflunomide—Paraesthesia—Prednisolone—ankylosing spondylitis	8.42e-05	0.00113	CcSEcCtD
Leflunomide—Tachycardia—Triamcinolone—ankylosing spondylitis	8.42e-05	0.00113	CcSEcCtD
Leflunomide—Mental disorder—Prednisone—ankylosing spondylitis	8.4e-05	0.00113	CcSEcCtD
Leflunomide—Tachycardia—Methylprednisolone—ankylosing spondylitis	8.4e-05	0.00112	CcSEcCtD
Leflunomide—Skin disorder—Methylprednisolone—ankylosing spondylitis	8.36e-05	0.00112	CcSEcCtD
Leflunomide—Malnutrition—Prednisone—ankylosing spondylitis	8.35e-05	0.00112	CcSEcCtD
Leflunomide—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	8.34e-05	0.00112	CcSEcCtD
Leflunomide—Agranulocytosis—Methotrexate—ankylosing spondylitis	8.33e-05	0.00112	CcSEcCtD
Leflunomide—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	8.32e-05	0.00111	CcSEcCtD
Leflunomide—Hypertension—Betamethasone—ankylosing spondylitis	8.28e-05	0.00111	CcSEcCtD
Leflunomide—Hypertension—Dexamethasone—ankylosing spondylitis	8.28e-05	0.00111	CcSEcCtD
Leflunomide—Myalgia—Dexamethasone—ankylosing spondylitis	8.16e-05	0.00109	CcSEcCtD
Leflunomide—Myalgia—Betamethasone—ankylosing spondylitis	8.16e-05	0.00109	CcSEcCtD
Leflunomide—Anxiety—Dexamethasone—ankylosing spondylitis	8.13e-05	0.00109	CcSEcCtD
Leflunomide—Anxiety—Betamethasone—ankylosing spondylitis	8.13e-05	0.00109	CcSEcCtD
Leflunomide—Discomfort—Betamethasone—ankylosing spondylitis	8.06e-05	0.00108	CcSEcCtD
Leflunomide—Discomfort—Dexamethasone—ankylosing spondylitis	8.06e-05	0.00108	CcSEcCtD
Leflunomide—Haemoglobin—Methotrexate—ankylosing spondylitis	8.06e-05	0.00108	CcSEcCtD
Leflunomide—Hypotension—Methylprednisolone—ankylosing spondylitis	8.04e-05	0.00108	CcSEcCtD
Leflunomide—Pain—Prednisolone—ankylosing spondylitis	8.02e-05	0.00107	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—ankylosing spondylitis	8.02e-05	0.00107	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—ankylosing spondylitis	8.02e-05	0.00107	CcSEcCtD
Leflunomide—Pharyngitis—Methotrexate—ankylosing spondylitis	7.96e-05	0.00107	CcSEcCtD
Leflunomide—Urinary tract disorder—Methotrexate—ankylosing spondylitis	7.92e-05	0.00106	CcSEcCtD
Leflunomide—Vision blurred—Prednisone—ankylosing spondylitis	7.87e-05	0.00105	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—ankylosing spondylitis	7.86e-05	0.00105	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	7.86e-05	0.00105	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	7.84e-05	0.00105	CcSEcCtD
Leflunomide—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	7.82e-05	0.00105	CcSEcCtD
Leflunomide—Anaphylactic shock—Betamethasone—ankylosing spondylitis	7.82e-05	0.00105	CcSEcCtD
Leflunomide—Insomnia—Triamcinolone—ankylosing spondylitis	7.8e-05	0.00104	CcSEcCtD
Leflunomide—Insomnia—Methylprednisolone—ankylosing spondylitis	7.78e-05	0.00104	CcSEcCtD
Leflunomide—Infection—Dexamethasone—ankylosing spondylitis	7.77e-05	0.00104	CcSEcCtD
Leflunomide—Infection—Betamethasone—ankylosing spondylitis	7.77e-05	0.00104	CcSEcCtD
Leflunomide—Ill-defined disorder—Prednisone—ankylosing spondylitis	7.75e-05	0.00104	CcSEcCtD
Leflunomide—Paraesthesia—Triamcinolone—ankylosing spondylitis	7.74e-05	0.00104	CcSEcCtD
Leflunomide—Feeling abnormal—Prednisolone—ankylosing spondylitis	7.73e-05	0.00103	CcSEcCtD
Leflunomide—Paraesthesia—Methylprednisolone—ankylosing spondylitis	7.73e-05	0.00103	CcSEcCtD
Leflunomide—Anaemia—Prednisone—ankylosing spondylitis	7.72e-05	0.00103	CcSEcCtD
Leflunomide—Dyspnoea—Triamcinolone—ankylosing spondylitis	7.69e-05	0.00103	CcSEcCtD
Leflunomide—Nervous system disorder—Dexamethasone—ankylosing spondylitis	7.67e-05	0.00103	CcSEcCtD
Leflunomide—Nervous system disorder—Betamethasone—ankylosing spondylitis	7.67e-05	0.00103	CcSEcCtD
Leflunomide—Thrombocytopenia—Betamethasone—ankylosing spondylitis	7.66e-05	0.00103	CcSEcCtD
Leflunomide—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	7.66e-05	0.00103	CcSEcCtD
Leflunomide—Tachycardia—Dexamethasone—ankylosing spondylitis	7.64e-05	0.00102	CcSEcCtD
Leflunomide—Tachycardia—Betamethasone—ankylosing spondylitis	7.64e-05	0.00102	CcSEcCtD
Leflunomide—Angioedema—Prednisone—ankylosing spondylitis	7.63e-05	0.00102	CcSEcCtD
Leflunomide—Dyspepsia—Triamcinolone—ankylosing spondylitis	7.59e-05	0.00102	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—ankylosing spondylitis	7.58e-05	0.00101	CcSEcCtD
Leflunomide—Dyspepsia—Methylprednisolone—ankylosing spondylitis	7.57e-05	0.00101	CcSEcCtD
Leflunomide—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	7.56e-05	0.00101	CcSEcCtD
Leflunomide—Hyperhidrosis—Betamethasone—ankylosing spondylitis	7.56e-05	0.00101	CcSEcCtD
Leflunomide—Malaise—Prednisone—ankylosing spondylitis	7.53e-05	0.00101	CcSEcCtD
Leflunomide—Vertigo—Prednisone—ankylosing spondylitis	7.5e-05	0.001	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—ankylosing spondylitis	7.49e-05	0.001	CcSEcCtD
Leflunomide—Anorexia—Betamethasone—ankylosing spondylitis	7.46e-05	0.000999	CcSEcCtD
Leflunomide—Anorexia—Dexamethasone—ankylosing spondylitis	7.46e-05	0.000999	CcSEcCtD
Leflunomide—Urticaria—Prednisolone—ankylosing spondylitis	7.45e-05	0.000998	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—ankylosing spondylitis	7.44e-05	0.000996	CcSEcCtD
Leflunomide—Fatigue—Triamcinolone—ankylosing spondylitis	7.43e-05	0.000996	CcSEcCtD
Leflunomide—Fatigue—Methylprednisolone—ankylosing spondylitis	7.42e-05	0.000993	CcSEcCtD
Leflunomide—Pain—Triamcinolone—ankylosing spondylitis	7.37e-05	0.000987	CcSEcCtD
Leflunomide—Hypotension—Dexamethasone—ankylosing spondylitis	7.31e-05	0.000979	CcSEcCtD
Leflunomide—Hypotension—Betamethasone—ankylosing spondylitis	7.31e-05	0.000979	CcSEcCtD
Leflunomide—Immune system disorder—Methotrexate—ankylosing spondylitis	7.24e-05	0.000969	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—ankylosing spondylitis	7.22e-05	0.000967	CcSEcCtD
Leflunomide—Hypertension—Prednisone—ankylosing spondylitis	7.21e-05	0.000965	CcSEcCtD
Leflunomide—Chills—Methotrexate—ankylosing spondylitis	7.19e-05	0.000963	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	7.13e-05	0.000955	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	7.13e-05	0.000955	CcSEcCtD
Leflunomide—Myalgia—Prednisone—ankylosing spondylitis	7.11e-05	0.000952	CcSEcCtD
Leflunomide—Arthralgia—Prednisone—ankylosing spondylitis	7.11e-05	0.000952	CcSEcCtD
Leflunomide—Feeling abnormal—Triamcinolone—ankylosing spondylitis	7.11e-05	0.000952	CcSEcCtD
Leflunomide—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	7.09e-05	0.000949	CcSEcCtD
Leflunomide—Anxiety—Prednisone—ankylosing spondylitis	7.08e-05	0.000949	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—ankylosing spondylitis	7.08e-05	0.000948	CcSEcCtD
Leflunomide—Insomnia—Dexamethasone—ankylosing spondylitis	7.08e-05	0.000948	CcSEcCtD
Leflunomide—Insomnia—Betamethasone—ankylosing spondylitis	7.08e-05	0.000948	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	7.06e-05	0.000945	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	7.04e-05	0.000942	CcSEcCtD
Leflunomide—Paraesthesia—Betamethasone—ankylosing spondylitis	7.03e-05	0.000941	CcSEcCtD
Leflunomide—Paraesthesia—Dexamethasone—ankylosing spondylitis	7.03e-05	0.000941	CcSEcCtD
Leflunomide—Discomfort—Prednisone—ankylosing spondylitis	7.02e-05	0.00094	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—ankylosing spondylitis	7.02e-05	0.00094	CcSEcCtD
Leflunomide—Malnutrition—Methotrexate—ankylosing spondylitis	6.98e-05	0.000934	CcSEcCtD
Leflunomide—Hypersensitivity—Prednisolone—ankylosing spondylitis	6.91e-05	0.000925	CcSEcCtD
Leflunomide—Dyspepsia—Betamethasone—ankylosing spondylitis	6.89e-05	0.000922	CcSEcCtD
Leflunomide—Dyspepsia—Dexamethasone—ankylosing spondylitis	6.89e-05	0.000922	CcSEcCtD
Leflunomide—Urticaria—Triamcinolone—ankylosing spondylitis	6.85e-05	0.000917	CcSEcCtD
Leflunomide—Urticaria—Methylprednisolone—ankylosing spondylitis	6.84e-05	0.000915	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—ankylosing spondylitis	6.83e-05	0.000915	CcSEcCtD
Leflunomide—Body temperature increased—Triamcinolone—ankylosing spondylitis	6.82e-05	0.000913	CcSEcCtD
Leflunomide—Anaphylactic shock—Prednisone—ankylosing spondylitis	6.81e-05	0.000912	CcSEcCtD
Leflunomide—Abdominal pain—Methylprednisolone—ankylosing spondylitis	6.8e-05	0.000911	CcSEcCtD
Leflunomide—Decreased appetite—Dexamethasone—ankylosing spondylitis	6.8e-05	0.000911	CcSEcCtD
Leflunomide—Decreased appetite—Betamethasone—ankylosing spondylitis	6.8e-05	0.000911	CcSEcCtD
Leflunomide—Infection—Prednisone—ankylosing spondylitis	6.77e-05	0.000906	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	6.76e-05	0.000905	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	6.76e-05	0.000905	CcSEcCtD
Leflunomide—Back pain—Methotrexate—ankylosing spondylitis	6.75e-05	0.000904	CcSEcCtD
Leflunomide—Fatigue—Dexamethasone—ankylosing spondylitis	6.75e-05	0.000903	CcSEcCtD
Leflunomide—Fatigue—Betamethasone—ankylosing spondylitis	6.75e-05	0.000903	CcSEcCtD
Leflunomide—Pain—Dexamethasone—ankylosing spondylitis	6.69e-05	0.000896	CcSEcCtD
Leflunomide—Pain—Betamethasone—ankylosing spondylitis	6.69e-05	0.000896	CcSEcCtD
Leflunomide—Nervous system disorder—Prednisone—ankylosing spondylitis	6.68e-05	0.000895	CcSEcCtD
Leflunomide—Tachycardia—Prednisone—ankylosing spondylitis	6.65e-05	0.000891	CcSEcCtD
Leflunomide—Skin disorder—Prednisone—ankylosing spondylitis	6.62e-05	0.000886	CcSEcCtD
Leflunomide—Hyperhidrosis—Prednisone—ankylosing spondylitis	6.59e-05	0.000882	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—ankylosing spondylitis	6.58e-05	0.000881	CcSEcCtD
Leflunomide—Anorexia—Prednisone—ankylosing spondylitis	6.5e-05	0.00087	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—ankylosing spondylitis	6.47e-05	0.000867	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—ankylosing spondylitis	6.45e-05	0.000864	CcSEcCtD
Leflunomide—Feeling abnormal—Betamethasone—ankylosing spondylitis	6.45e-05	0.000863	CcSEcCtD
Leflunomide—Feeling abnormal—Dexamethasone—ankylosing spondylitis	6.45e-05	0.000863	CcSEcCtD
Leflunomide—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	6.4e-05	0.000857	CcSEcCtD
Leflunomide—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	6.4e-05	0.000857	CcSEcCtD
Leflunomide—Hypersensitivity—Triamcinolone—ankylosing spondylitis	6.35e-05	0.000851	CcSEcCtD
Leflunomide—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	6.34e-05	0.000849	CcSEcCtD
Leflunomide—Malaise—Methotrexate—ankylosing spondylitis	6.29e-05	0.000843	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—ankylosing spondylitis	6.27e-05	0.000839	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—ankylosing spondylitis	6.25e-05	0.000836	CcSEcCtD
Leflunomide—Urticaria—Dexamethasone—ankylosing spondylitis	6.22e-05	0.000832	CcSEcCtD
Leflunomide—Urticaria—Betamethasone—ankylosing spondylitis	6.22e-05	0.000832	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	6.21e-05	0.000831	CcSEcCtD
Leflunomide—Dizziness—Prednisolone—ankylosing spondylitis	6.2e-05	0.00083	CcSEcCtD
Leflunomide—Asthenia—Triamcinolone—ankylosing spondylitis	6.19e-05	0.000828	CcSEcCtD
Leflunomide—Body temperature increased—Betamethasone—ankylosing spondylitis	6.19e-05	0.000828	CcSEcCtD
Leflunomide—Abdominal pain—Betamethasone—ankylosing spondylitis	6.19e-05	0.000828	CcSEcCtD
Leflunomide—Abdominal pain—Dexamethasone—ankylosing spondylitis	6.19e-05	0.000828	CcSEcCtD
Leflunomide—Body temperature increased—Dexamethasone—ankylosing spondylitis	6.19e-05	0.000828	CcSEcCtD
Leflunomide—Asthenia—Methylprednisolone—ankylosing spondylitis	6.17e-05	0.000827	CcSEcCtD
Leflunomide—Insomnia—Prednisone—ankylosing spondylitis	6.16e-05	0.000825	CcSEcCtD
Leflunomide—Paraesthesia—Prednisone—ankylosing spondylitis	6.12e-05	0.000819	CcSEcCtD
Leflunomide—Pruritus—Triamcinolone—ankylosing spondylitis	6.1e-05	0.000817	CcSEcCtD
Leflunomide—Cough—Methotrexate—ankylosing spondylitis	6.09e-05	0.000815	CcSEcCtD
Leflunomide—Pruritus—Methylprednisolone—ankylosing spondylitis	6.09e-05	0.000815	CcSEcCtD
Leflunomide—Dyspepsia—Prednisone—ankylosing spondylitis	6e-05	0.000803	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—ankylosing spondylitis	5.94e-05	0.000795	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—ankylosing spondylitis	5.94e-05	0.000795	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—ankylosing spondylitis	5.94e-05	0.000795	CcSEcCtD
Leflunomide—Decreased appetite—Prednisone—ankylosing spondylitis	5.92e-05	0.000793	CcSEcCtD
Leflunomide—Rash—Prednisolone—ankylosing spondylitis	5.91e-05	0.000792	CcSEcCtD
Leflunomide—Dermatitis—Prednisolone—ankylosing spondylitis	5.91e-05	0.000791	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	5.9e-05	0.00079	CcSEcCtD
Leflunomide—Diarrhoea—Methylprednisolone—ankylosing spondylitis	5.89e-05	0.000788	CcSEcCtD
Leflunomide—Fatigue—Prednisone—ankylosing spondylitis	5.87e-05	0.000787	CcSEcCtD
Leflunomide—Headache—Prednisolone—ankylosing spondylitis	5.87e-05	0.000787	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—ankylosing spondylitis	5.87e-05	0.000786	CcSEcCtD
Leflunomide—Constipation—Prednisone—ankylosing spondylitis	5.83e-05	0.00078	CcSEcCtD
Leflunomide—Dizziness—Triamcinolone—ankylosing spondylitis	5.7e-05	0.000764	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—ankylosing spondylitis	5.69e-05	0.000763	CcSEcCtD
Leflunomide—Dizziness—Methylprednisolone—ankylosing spondylitis	5.69e-05	0.000762	CcSEcCtD
Leflunomide—Infection—Methotrexate—ankylosing spondylitis	5.66e-05	0.000758	CcSEcCtD
Leflunomide—Feeling abnormal—Prednisone—ankylosing spondylitis	5.62e-05	0.000752	CcSEcCtD
Leflunomide—Asthenia—Dexamethasone—ankylosing spondylitis	5.61e-05	0.000752	CcSEcCtD
Leflunomide—Asthenia—Betamethasone—ankylosing spondylitis	5.61e-05	0.000752	CcSEcCtD
Leflunomide—Nervous system disorder—Methotrexate—ankylosing spondylitis	5.58e-05	0.000748	CcSEcCtD
Leflunomide—Thrombocytopenia—Methotrexate—ankylosing spondylitis	5.58e-05	0.000747	CcSEcCtD
Leflunomide—Gastrointestinal pain—Prednisone—ankylosing spondylitis	5.57e-05	0.000746	CcSEcCtD
Leflunomide—Nausea—Prednisolone—ankylosing spondylitis	5.57e-05	0.000746	CcSEcCtD
Leflunomide—Pruritus—Betamethasone—ankylosing spondylitis	5.54e-05	0.000741	CcSEcCtD
Leflunomide—Pruritus—Dexamethasone—ankylosing spondylitis	5.54e-05	0.000741	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—ankylosing spondylitis	5.53e-05	0.000741	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—ankylosing spondylitis	5.51e-05	0.000737	CcSEcCtD
Leflunomide—Vomiting—Triamcinolone—ankylosing spondylitis	5.48e-05	0.000734	CcSEcCtD
Leflunomide—Vomiting—Methylprednisolone—ankylosing spondylitis	5.47e-05	0.000733	CcSEcCtD
Leflunomide—Rash—Triamcinolone—ankylosing spondylitis	5.44e-05	0.000728	CcSEcCtD
Leflunomide—Dermatitis—Triamcinolone—ankylosing spondylitis	5.43e-05	0.000727	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—ankylosing spondylitis	5.43e-05	0.000727	CcSEcCtD
Leflunomide—Rash—Methylprednisolone—ankylosing spondylitis	5.43e-05	0.000726	CcSEcCtD
Leflunomide—Dermatitis—Methylprednisolone—ankylosing spondylitis	5.42e-05	0.000726	CcSEcCtD
Leflunomide—Urticaria—Prednisone—ankylosing spondylitis	5.41e-05	0.000725	CcSEcCtD
Leflunomide—Headache—Triamcinolone—ankylosing spondylitis	5.4e-05	0.000723	CcSEcCtD
Leflunomide—Headache—Methylprednisolone—ankylosing spondylitis	5.39e-05	0.000722	CcSEcCtD
Leflunomide—Abdominal pain—Prednisone—ankylosing spondylitis	5.39e-05	0.000721	CcSEcCtD
Leflunomide—Body temperature increased—Prednisone—ankylosing spondylitis	5.39e-05	0.000721	CcSEcCtD
Leflunomide—Diarrhoea—Betamethasone—ankylosing spondylitis	5.35e-05	0.000717	CcSEcCtD
Leflunomide—Diarrhoea—Dexamethasone—ankylosing spondylitis	5.35e-05	0.000717	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—ankylosing spondylitis	5.32e-05	0.000713	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	5.19e-05	0.000695	CcSEcCtD
Leflunomide—Dizziness—Dexamethasone—ankylosing spondylitis	5.17e-05	0.000693	CcSEcCtD
Leflunomide—Dizziness—Betamethasone—ankylosing spondylitis	5.17e-05	0.000693	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—ankylosing spondylitis	5.15e-05	0.00069	CcSEcCtD
Leflunomide—Nausea—Triamcinolone—ankylosing spondylitis	5.12e-05	0.000686	CcSEcCtD
Leflunomide—Paraesthesia—Methotrexate—ankylosing spondylitis	5.11e-05	0.000685	CcSEcCtD
Leflunomide—Nausea—Methylprednisolone—ankylosing spondylitis	5.11e-05	0.000684	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—ankylosing spondylitis	5.08e-05	0.00068	CcSEcCtD
Leflunomide—Hypersensitivity—Prednisone—ankylosing spondylitis	5.02e-05	0.000672	CcSEcCtD
Leflunomide—Dyspepsia—Methotrexate—ankylosing spondylitis	5.01e-05	0.000671	CcSEcCtD
Leflunomide—Vomiting—Betamethasone—ankylosing spondylitis	4.98e-05	0.000666	CcSEcCtD
Leflunomide—Vomiting—Dexamethasone—ankylosing spondylitis	4.98e-05	0.000666	CcSEcCtD
Leflunomide—Decreased appetite—Methotrexate—ankylosing spondylitis	4.95e-05	0.000663	CcSEcCtD
Leflunomide—Rash—Dexamethasone—ankylosing spondylitis	4.93e-05	0.000661	CcSEcCtD
Leflunomide—Rash—Betamethasone—ankylosing spondylitis	4.93e-05	0.000661	CcSEcCtD
Leflunomide—Dermatitis—Betamethasone—ankylosing spondylitis	4.93e-05	0.00066	CcSEcCtD
Leflunomide—Dermatitis—Dexamethasone—ankylosing spondylitis	4.93e-05	0.00066	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	4.92e-05	0.000658	CcSEcCtD
Leflunomide—Fatigue—Methotrexate—ankylosing spondylitis	4.91e-05	0.000657	CcSEcCtD
Leflunomide—Headache—Dexamethasone—ankylosing spondylitis	4.9e-05	0.000656	CcSEcCtD
Leflunomide—Headache—Betamethasone—ankylosing spondylitis	4.9e-05	0.000656	CcSEcCtD
Leflunomide—Asthenia—Prednisone—ankylosing spondylitis	4.89e-05	0.000655	CcSEcCtD
Leflunomide—Pain—Methotrexate—ankylosing spondylitis	4.87e-05	0.000652	CcSEcCtD
Leflunomide—Pruritus—Prednisone—ankylosing spondylitis	4.82e-05	0.000646	CcSEcCtD
Leflunomide—Feeling abnormal—Methotrexate—ankylosing spondylitis	4.69e-05	0.000628	CcSEcCtD
Leflunomide—Diarrhoea—Prednisone—ankylosing spondylitis	4.66e-05	0.000624	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	4.66e-05	0.000624	CcSEcCtD
Leflunomide—Nausea—Dexamethasone—ankylosing spondylitis	4.65e-05	0.000622	CcSEcCtD
Leflunomide—Nausea—Betamethasone—ankylosing spondylitis	4.65e-05	0.000622	CcSEcCtD
Leflunomide—Urticaria—Methotrexate—ankylosing spondylitis	4.52e-05	0.000606	CcSEcCtD
Leflunomide—Dizziness—Prednisone—ankylosing spondylitis	4.51e-05	0.000603	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—ankylosing spondylitis	4.5e-05	0.000603	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—ankylosing spondylitis	4.5e-05	0.000603	CcSEcCtD
Leflunomide—Vomiting—Prednisone—ankylosing spondylitis	4.33e-05	0.00058	CcSEcCtD
Leflunomide—Rash—Prednisone—ankylosing spondylitis	4.3e-05	0.000575	CcSEcCtD
Leflunomide—Dermatitis—Prednisone—ankylosing spondylitis	4.29e-05	0.000575	CcSEcCtD
Leflunomide—Headache—Prednisone—ankylosing spondylitis	4.27e-05	0.000572	CcSEcCtD
Leflunomide—Hypersensitivity—Methotrexate—ankylosing spondylitis	4.2e-05	0.000562	CcSEcCtD
Leflunomide—Asthenia—Methotrexate—ankylosing spondylitis	4.09e-05	0.000547	CcSEcCtD
Leflunomide—Nausea—Prednisone—ankylosing spondylitis	4.05e-05	0.000542	CcSEcCtD
Leflunomide—Pruritus—Methotrexate—ankylosing spondylitis	4.03e-05	0.00054	CcSEcCtD
Leflunomide—Diarrhoea—Methotrexate—ankylosing spondylitis	3.9e-05	0.000522	CcSEcCtD
Leflunomide—Dizziness—Methotrexate—ankylosing spondylitis	3.77e-05	0.000504	CcSEcCtD
Leflunomide—Vomiting—Methotrexate—ankylosing spondylitis	3.62e-05	0.000485	CcSEcCtD
Leflunomide—Rash—Methotrexate—ankylosing spondylitis	3.59e-05	0.000481	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—ankylosing spondylitis	3.59e-05	0.00048	CcSEcCtD
Leflunomide—Headache—Methotrexate—ankylosing spondylitis	3.57e-05	0.000478	CcSEcCtD
Leflunomide—Nausea—Methotrexate—ankylosing spondylitis	3.38e-05	0.000453	CcSEcCtD
